Wang Weidong, Li Chunling, Kwon Tae-Hwan, Miller R Tyler, Knepper Mark A, Frøkiaer Jørgen, Nielsen Søren
The Water and Salt Research Center, University of Aarhus, DK-8000 Aarhus C, Denmark.
Am J Physiol Renal Physiol. 2004 Mar;286(3):F534-45. doi: 10.1152/ajprenal.00044.2003. Epub 2003 Nov 18.
The purpose of this study was to evaluate whether the natriuresis and polyuria seen in parathyroid hormone (PTH)-induced hypercalcemia are associated with dysregulation of renal Na transporters. Rats were infused with three different doses of human PTH [PTH (1-34); 7.5, 10, and 15 microg.kg(-1).day(-1) s.c.] or vehicle for 48 h using osmotic minipumps. The rats treated with PTH developed significant hypercalcemia (plasma total calcium levels: 2.71 +/- 0.03, 2.77 +/- 0.02, and 3.42 +/- 0.06 mmol/l, respectively, P < 0.05 compared with corresponding controls). The rats with severe hypercalcemia induced by high-dose PTH developed a decreased glomerular filtration rate (GFR), increased urine output, reduced urinary osmolality, increased urinary Na excretion, and fractional excretion of Na. This was associated with downregulation (calculated as a fraction of control levels) of whole kidney expression of type 2 Na-P(i) cotransporter (NaPi-2; 16 +/- 6%), type 3 Na/H exchanger (NHE3; 42 +/- 7%), Na-K-ATPase (55 +/- 2%), and bumetanide-sensitive Na-K-2Cl cotransporter (BSC-1; 25 +/- 4%). In contrast, an upregulation of the Ca(2+)-sensing receptor (CaR) was observed. Rats treated with moderate-dose PTH exhibited unchanged GFR but decreased urinary concentration. The whole kidney expression of NHE3 (52 +/- 8%) and NaPi-2 (26 +/- 5%) was persistently decreased, whereas BSC-1 and Na-K-ATPase protein levels were not altered. CaR expression was also increased. Moreover, rats treated with low-dose PTH showed very mild hypercalcemia but unchanged GFR, normal urinary concentration, and unchanged expression of Na transporters and CaR. In conclusion, the reduced expression of major renal Na transporters is likely to play a role in the increased urinary Na excretion and decreased urinary concentration in rats with PTH-induced hypercalcemia. Moreover, the increase in the CaR in the thick ascending limb (TAL) may indicate a potential role of the CaR in inhibiting Na transport in the TAL.
本研究的目的是评估甲状旁腺激素(PTH)诱导的高钙血症中出现的利钠和多尿是否与肾钠转运体的调节异常有关。使用渗透微型泵给大鼠皮下注射三种不同剂量的人PTH [PTH(1 - 34);7.5、10和15μg·kg⁻¹·天⁻¹] 或赋形剂,持续48小时。接受PTH治疗的大鼠出现了明显的高钙血症(血浆总钙水平分别为:2.71±0.03、2.77±0.02和3.42±0.06 mmol/L,与相应对照组相比,P < 0.05)。高剂量PTH诱导的严重高钙血症大鼠肾小球滤过率(GFR)降低、尿量增加、尿渗透压降低、尿钠排泄增加以及钠分数排泄增加。这与2型钠 - 无机磷共转运体(NaPi - 2;16±6%)、3型钠/氢交换体(NHE3;42±7%)、钠钾ATP酶(55±2%)和布美他尼敏感的钠 - 钾 - 2氯共转运体(BSC - 1;25±4%)的全肾表达下调(以对照水平的分数计算)有关。相反,观察到钙敏感受体(CaR)上调。中等剂量PTH治疗的大鼠GFR未改变,但尿浓缩功能降低。NHE3(52±8%)和NaPi - 2(26±5%)的全肾表达持续降低,而BSC - 1和钠钾ATP酶蛋白水平未改变。CaR表达也增加。此外,低剂量PTH治疗的大鼠表现出非常轻微的高钙血症,但GFR未改变、尿浓缩功能正常,钠转运体和CaR的表达也未改变。总之,主要肾钠转运体表达降低可能在PTH诱导的高钙血症大鼠尿钠排泄增加和尿浓缩功能降低中起作用。此外,厚壁升支(TAL)中CaR的增加可能表明CaR在抑制TAL中的钠转运方面具有潜在作用。